0001209191-22-005080.txt : 20220126
0001209191-22-005080.hdr.sgml : 20220126
20220126163417
ACCESSION NUMBER: 0001209191-22-005080
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220124
FILED AS OF DATE: 20220126
DATE AS OF CHANGE: 20220126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clague Laura
CENTRAL INDEX KEY: 0001388773
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 22558467
MAIL ADDRESS:
STREET 1: 370 PARK RANCH PLACE
CITY: ESCONDIDO
STATE: CA
ZIP: 92025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-24
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001388773
Clague Laura
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300
SAN DIEGO
CA
92130
0
1
0
0
Chief Financial Officer
Common Stock
2022-01-24
4
S
0
2063
24.98
D
29253
D
The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2022-01-26